4-isopropylcyclohexylamine hydrochloride | 33024-54-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-isopropylcyclohexylamine hydrochloride
• 英文别名: 4-isopropylcyclohexylamine hydrochloride salt；trans-4-Isopropylcyclohexylamine hydrochloride；4-propan-2-ylcyclohexan-1-amine;hydrochloride
• CAS: 33024-54-3
• 化学式: C₉H₁₉N*ClH
• 分子量: 177.717
• InChiKey: PMCLSVNRQSZZRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.58
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [EN] BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RÉCEPTEURS ARYLES ET HÉTÉROARYLES BICYCLIQUES
  申请人：PROSIDION LTD

  公开号：WO2009030962A1

  公开（公告）日：2009-03-12

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.

  化合物的化学式（I）或其药用盐是阿片受体调节剂，例如μ阿片受体拮抗剂、中性拮抗剂或逆向激动剂，可用于治疗肥胖等疾病。
• Urea Glucokinase Activators
  申请人：Lau Jesper

  公开号：US20090105482A1

  公开（公告）日：2009-04-23

  The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

  本发明提供了一种具有一般式(I)的化合物，其中取代基在申请书中进一步定义，以及在所附的实施例中进一步描述的本发明的其他实施例。本发明还提供了使用该化合物制备药物治疗各种疾病的用途，例如治疗2型糖尿病。
• BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS
  申请人：Bloxham Jason

  公开号：US20100267780A1

  公开（公告）日：2010-10-21

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.

  式(I)的化合物或其药学上可接受的盐，是阿片受体调节剂，例如μ-阿片受体拮抗剂、中性拮抗剂或反向激动剂，可用于治疗肥胖等疾病。
• BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Bloxham Jason

  公开号：US20100173886A1

  公开（公告）日：2010-07-08

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

  化合物式(I)或其药学上可接受的盐，是阿片受体调节剂，例如μ-阿片受体拮抗剂，中性拮抗剂或倒向激动剂，并且可用于治疗代谢性疾病，包括肥胖症。
• Urea glucokinase activators
  申请人：NOVO NORDISK A/S

  公开号：EP2377856A1

  公开（公告）日：2011-10-19

  The invention provides a compound of general formula (1) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

  本发明提供了通式（1）的化合物 其中取代基在本申请中进一步定义，以及在所附实施例中描述的本发明的进一步实施例。 本发明还提供了本发明化合物用于制备治疗各种疾病的药物的用途，例如用于治疗 2 型糖尿病。